Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity

Ussama M. Abdel-Motal, Kim Wigglesworth, Uri Galili

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

α-Gal glycolipids capable of converting tumors into endogenous vaccines, have α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) and are extracted from rabbit RBC membranes. α-Gal epitopes bind anti-Gal, the most abundant natural antibody in humans constituting 1% of immunoglobulins. α-Gal glycolipids insert into tumor cell membranes, bind anti-Gal and activate complement. The complement cleavage peptides C5a and C3a recruit inflammatory cells and APC into the treated lesion. Anti-Gal further opsonizes the tumor cells and targets them for effective uptake by recruited APC, via Fcγ receptors. These APC transport internalized tumor cells to draining lymph nodes, and present immunogenic tumor antigen peptides for activation of tumor specific T cells. The present study demonstrates the ability of α-gal glycolipids treatment to prevent development of metastases at distant sites and to protect against tumor challenge in the treated mice. Adoptive transfer studies indicate that this protective immune response is mediated by CD8+ T cells, activated by tumor lesions turned vaccine. This T cell activation is potent enough to overcome the suppressive activity of Treg cells present in tumor bearing mice, however it does not elicit an autoimmune response against antigens on normal cells. Insertion of α-gal glycolipids and subsequent binding of anti-Gal are further demonstrated with human melanoma cells, suggesting that intratumoral injection of α-gal glycolipids is likely to elicit a protective immune response against micrometastases also in cancer patients.

Original languageEnglish
Pages (from-to)1545-1556
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume58
Issue number10
DOIs
Publication statusPublished - Oct 2009
Externally publishedYes

Fingerprint

Glycolipids
T-Lymphocytes
Injections
Neoplasms
Epitopes
Vaccines
Thomsen-Friedenreich antibodies
Neoplasm Micrometastasis
Peptides
Adoptive Transfer
Fc Receptors
Neoplasm Antigens
Regulatory T-Lymphocytes
Autoimmunity
Immunoglobulins
Melanoma
Lymph Nodes
Cell Membrane
Neoplasm Metastasis
Rabbits

Keywords

  • α-Gal glycolipids
  • Anti-Gal antibody
  • Anti-tumor immune response
  • Cancer immunotherapy
  • Tumor vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. / Abdel-Motal, Ussama M.; Wigglesworth, Kim; Galili, Uri.

In: Cancer Immunology, Immunotherapy, Vol. 58, No. 10, 10.2009, p. 1545-1556.

Research output: Contribution to journalArticle

@article{d530616cd3e54356b10959ed379e7f77,
title = "Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity",
abstract = "α-Gal glycolipids capable of converting tumors into endogenous vaccines, have α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) and are extracted from rabbit RBC membranes. α-Gal epitopes bind anti-Gal, the most abundant natural antibody in humans constituting 1{\%} of immunoglobulins. α-Gal glycolipids insert into tumor cell membranes, bind anti-Gal and activate complement. The complement cleavage peptides C5a and C3a recruit inflammatory cells and APC into the treated lesion. Anti-Gal further opsonizes the tumor cells and targets them for effective uptake by recruited APC, via Fcγ receptors. These APC transport internalized tumor cells to draining lymph nodes, and present immunogenic tumor antigen peptides for activation of tumor specific T cells. The present study demonstrates the ability of α-gal glycolipids treatment to prevent development of metastases at distant sites and to protect against tumor challenge in the treated mice. Adoptive transfer studies indicate that this protective immune response is mediated by CD8+ T cells, activated by tumor lesions turned vaccine. This T cell activation is potent enough to overcome the suppressive activity of Treg cells present in tumor bearing mice, however it does not elicit an autoimmune response against antigens on normal cells. Insertion of α-gal glycolipids and subsequent binding of anti-Gal are further demonstrated with human melanoma cells, suggesting that intratumoral injection of α-gal glycolipids is likely to elicit a protective immune response against micrometastases also in cancer patients.",
keywords = "α-Gal glycolipids, Anti-Gal antibody, Anti-tumor immune response, Cancer immunotherapy, Tumor vaccine",
author = "Abdel-Motal, {Ussama M.} and Kim Wigglesworth and Uri Galili",
year = "2009",
month = "10",
doi = "10.1007/s00262-009-0662-2",
language = "English",
volume = "58",
pages = "1545--1556",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "10",

}

TY - JOUR

T1 - Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity

AU - Abdel-Motal, Ussama M.

AU - Wigglesworth, Kim

AU - Galili, Uri

PY - 2009/10

Y1 - 2009/10

N2 - α-Gal glycolipids capable of converting tumors into endogenous vaccines, have α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) and are extracted from rabbit RBC membranes. α-Gal epitopes bind anti-Gal, the most abundant natural antibody in humans constituting 1% of immunoglobulins. α-Gal glycolipids insert into tumor cell membranes, bind anti-Gal and activate complement. The complement cleavage peptides C5a and C3a recruit inflammatory cells and APC into the treated lesion. Anti-Gal further opsonizes the tumor cells and targets them for effective uptake by recruited APC, via Fcγ receptors. These APC transport internalized tumor cells to draining lymph nodes, and present immunogenic tumor antigen peptides for activation of tumor specific T cells. The present study demonstrates the ability of α-gal glycolipids treatment to prevent development of metastases at distant sites and to protect against tumor challenge in the treated mice. Adoptive transfer studies indicate that this protective immune response is mediated by CD8+ T cells, activated by tumor lesions turned vaccine. This T cell activation is potent enough to overcome the suppressive activity of Treg cells present in tumor bearing mice, however it does not elicit an autoimmune response against antigens on normal cells. Insertion of α-gal glycolipids and subsequent binding of anti-Gal are further demonstrated with human melanoma cells, suggesting that intratumoral injection of α-gal glycolipids is likely to elicit a protective immune response against micrometastases also in cancer patients.

AB - α-Gal glycolipids capable of converting tumors into endogenous vaccines, have α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) and are extracted from rabbit RBC membranes. α-Gal epitopes bind anti-Gal, the most abundant natural antibody in humans constituting 1% of immunoglobulins. α-Gal glycolipids insert into tumor cell membranes, bind anti-Gal and activate complement. The complement cleavage peptides C5a and C3a recruit inflammatory cells and APC into the treated lesion. Anti-Gal further opsonizes the tumor cells and targets them for effective uptake by recruited APC, via Fcγ receptors. These APC transport internalized tumor cells to draining lymph nodes, and present immunogenic tumor antigen peptides for activation of tumor specific T cells. The present study demonstrates the ability of α-gal glycolipids treatment to prevent development of metastases at distant sites and to protect against tumor challenge in the treated mice. Adoptive transfer studies indicate that this protective immune response is mediated by CD8+ T cells, activated by tumor lesions turned vaccine. This T cell activation is potent enough to overcome the suppressive activity of Treg cells present in tumor bearing mice, however it does not elicit an autoimmune response against antigens on normal cells. Insertion of α-gal glycolipids and subsequent binding of anti-Gal are further demonstrated with human melanoma cells, suggesting that intratumoral injection of α-gal glycolipids is likely to elicit a protective immune response against micrometastases also in cancer patients.

KW - α-Gal glycolipids

KW - Anti-Gal antibody

KW - Anti-tumor immune response

KW - Cancer immunotherapy

KW - Tumor vaccine

UR - http://www.scopus.com/inward/record.url?scp=68549140182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549140182&partnerID=8YFLogxK

U2 - 10.1007/s00262-009-0662-2

DO - 10.1007/s00262-009-0662-2

M3 - Article

VL - 58

SP - 1545

EP - 1556

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 10

ER -